Disease Report: Alzheimer's Disease

This automatically generated dataset of diseases-related information is compiled based on literature research and is provided for informational purposes only. While efforts have been made to ensure accuracy and comprehensiveness, the dataset may include inaccuracies, omissions, or biases inherent in the source materials. It should not be used as the basis for clinical, commercial, or policy decisions. Users are advised to consult relevant experts and primary sources to verify the information.

Pathogenesis Targets

Assays and Models

1. Hypothesis Summary:

The hypothesis posits that the accumulation of amyloid-beta (Aβ) protein in the brain leads to the formation of plaques, which are toxic to neurons and trigger a cascade of neurodegenerative processes, including tau hyperphosphorylation, inflammation, and neuronal death. This hypothesis is central to the amyloid cascade hypothesis, which suggests that Aβ accumulation is a primary event in the pathogenesis of Alzheimer's disease (AD).

2. Mechanism and Evidence:

Amyloid-beta Accumulation: Aβ is produced from the cleavage of amyloid precursor protein (APP) by beta-secretase and gamma-secretase. The accumulation of Aβ leads to the formation of insoluble plaques in the brain, which are toxic to neurons (Hampel et al., 2021, PMID: 34456336).
Tau Hyperphosphorylation: Aβ accumulation is associated with the hyperphosphorylation of tau protein, leading to the formation of neurofibrillary tangles. Studies show that Aβ oligomers can induce tau phosphorylation at AD-relevant epitopes (Selkoe & Hardy, 2016, PMID: 27025652).
Neuroinflammation: The presence of Aβ plaques activates microglia, leading to chronic neuroinflammation, which exacerbates neuronal damage and contributes to cognitive decline (Zhang et al., 2023, PMID: 36911732).

3. Clinical Evidence:

Clinical Trials: Recent trials of anti-Aβ therapies, such as aducanumab and lecanemab, have shown modest benefits in slowing cognitive decline in patients with early AD, supporting the role of Aβ in disease progression (Yadollahikhales & Rojas, 2023, PMID: 37490245).
Biomarker Studies: Low cerebrospinal fluid (CSF) Aβ42 levels and amyloid-PET positivity have been shown to precede clinical symptoms of AD, indicating that Aβ accumulation is an early event in the disease process (Selkoe & Hardy, 2016, PMID: 27025652).

4. Genetic Targets and Evidence:

APOE Gene: The apolipoprotein E (APOE) ε4 allele is a significant genetic risk factor for AD, associated with impaired Aβ clearance from the brain and increased risk of developing AD (Koutsodendris et al., 2022, PMID: 34460318).
Presenilin Mutations: Mutations in presenilin genes, which are part of the gamma-secretase complex, lead to increased production of Aβ and early-onset familial AD (Selkoe & Hardy, 2016, PMID: 27025652).

5. Protein Targets and Evidence:

Amyloid Precursor Protein (APP): Mutations in APP lead to increased Aβ production, supporting the role of Aβ in AD pathogenesis (Selkoe & Hardy, 2016, PMID: 27025652).
Tau Protein: Hyperphosphorylated tau is a hallmark of AD pathology, and its interaction with Aβ is critical for neurodegeneration (Zhang et al., 2021, PMID: 34239348).

6. Pathways and Evidence:

Amyloid Cascade Pathway: The accumulation of Aβ triggers a cascade of events leading to tau hyperphosphorylation and neurodegeneration. This pathway is supported by evidence showing that Aβ oligomers can induce tau phosphorylation and synaptic dysfunction (Selkoe & Hardy, 2016, PMID: 27025652).
Neuroinflammatory Pathway: Aβ-induced microglial activation leads to chronic inflammation, which contributes to neuronal death and cognitive decline (Zhang et al., 2023, PMID: 36911732).

7. Cellular Targets and Evidence:

Microglia: Activated microglia respond to Aβ accumulation, but chronic activation can lead to neurotoxicity and exacerbate AD pathology (Zhang et al., 2023, PMID: 36911732).
Neurons: Aβ toxicity directly affects neuronal health, leading to synaptic loss and cognitive impairment (Hampel et al., 2021, PMID: 34456336).

8. Tissue Targets and Evidence:

Brain Tissue: Aβ plaques and tau tangles are primarily found in the brain tissue of AD patients, correlating with cognitive deficits and neurodegeneration (Zheng & Wang, 2025, PMID: 38733347).
Blood-Brain Barrier (BBB): Dysfunction of the BBB contributes to the accumulation of Aβ and tau in the brain, leading to neuroinflammation and neuronal injury (Zenaro et al., 2017, PMID: 27425887).

9. Additional Context:

While the amyloid cascade hypothesis has been a dominant framework for understanding AD, it has faced criticism due to the complexity of the disease and the failure of many Aβ-targeting therapies in clinical trials. Alternative hypotheses, such as the neuroinflammation hypothesis and the role of metal ions in AD pathology, suggest that Aβ may not be the sole driver of neurodegeneration. The interplay between Aβ and tau, as well as other factors such as neuroinflammation and genetic predispositions, highlights the multifactorial nature of AD and the need for comprehensive treatment strategies that address multiple pathways (Harrison & Owen, 2016, PMID: 26729836; Chen et al., 2023, PMID: 36455485).

In conclusion, while there is substantial evidence supporting the hypothesis that Aβ accumulation leads to neurodegeneration through various mechanisms, there is also growing recognition of the complexity of AD pathology, necessitating a broader approach to understanding and treating this devastating disease.